SLNO Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Soleno Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.63 |
| 52 Week High | US$59.75 |
| 52 Week Low | US$26.38 |
| Beta | -1.44 |
| 11 Month Change | 1.85% |
| 3 Month Change | 20.73% |
| 1 Year Change | 95.11% |
| 33 Year Change | 446.03% |
| 5 Year Change | 138.04% |
| Change since IPO | -81.84% |
Recent News & Updates
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth
Nov 08
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Oct 10Recent updates
Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth
Nov 08Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Oct 10We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn
Mar 08Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Sep 20Soleno sheds 13% as 1-for-15 reverse stock split takes effect
Aug 26Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky
Aug 12Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment
Jul 20Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely
May 10We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate
Jan 24Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment
Jun 02Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?
Mar 23Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares
Jan 29
Soleno Therapeutics: Could Be Big Fish In The Small Pond
Jan 08Here's Why We're Not Too Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Dec 07Shareholder Returns
| SLNO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | -6.5% | -1.0% |
| 1Y | 95.1% | 14.6% | 30.3% |
Return vs Industry: SLNO exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: SLNO exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| SLNO volatility | |
|---|---|
| SLNO Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SLNO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SLNO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 33 | Anish Bhatnagar | soleno.life |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. Fundamentals Summary
| SLNO fundamental statistics | |
|---|---|
| Market cap | US$2.36b |
| Earnings (TTM) | -US$131.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-18.0x
P/E RatioIs SLNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLNO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$131.16m |
| Earnings | -US$131.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLNO perform over the long term?
See historical performance and comparison